ARQT
NASDAQArcutis Biotherapeutics, Inc.
Healthcare · Biotechnology
Price History
Learn Why It Moved
Educational concepts related to this stock
Volume Surge
Unusual trading volume indicates heightened interest — institutional activity or news-driven demand.
Momentum Rally
A significant upward move. Understanding what catalysts drive these moves is key to trading them.
Biotech Catalyst
Biotech stocks are often driven by FDA approvals, trial results, and regulatory news. Learn how binary catalysts work.
Insider Activity
Check if insiders have been buying or selling. Insider buying is one of the strongest signals in small cap trading.
Dilution Risk
Check SEC filings for active shelf registrations. Dilution is the #1 risk in small cap trading.
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.